Sodium cromoglycate (cas 15826-37-6) reduces short- and long-term consequences of status epilepticus in rats
-
Add time:09/24/2019 Source:sciencedirect.com
Several studies indicate that Sodium cromoglycate (cas 15826-37-6) (CG) induces neuroprotective effects in acute neurological conditions. The present study focused on investigating if the use of CG in rats during the post-status epilepticus (post-SE) period reduces the acute and long-term consequences of seizure activity. Our results revealed that animals that received a single dose of CG (50 mg/kg s.c.: subcutaneously) during the post-SE period showed a lower number of neurons in the process of dying in the dentate gyrus, hilus, cornu ammonis 1 (CA1), and CA3 of the dorsal hippocampus than the rats that received the vehicle. However, this effect was not evident in layers V–VI of the sensorimotor cortex or the lateral-posterior thalamic nucleus. A second experiment showed that animals that received CG subchronically (50 mg/kg s.c. every 12 h for 5 days followed by 24 mg/kg/day s.c. for 14 days using osmotic minipumps) after SE presented fewer generalized convulsive seizures and less neuronal damage in the lateral-posterior thalamic nucleus but not in the hippocampus or cortex. Our data indicate that CG can be used as a therapeutic strategy to reduce short- and long-term neuronal damage in the hippocampus and thalamus, respectively. The data also indicate that CG can reduce the expression of generalized convulsive spontaneous seizures when it is given during the latent period of epileptogenesis.
We also recommend Trading Suppliers and Manufacturers of Sodium cromoglycate (cas 15826-37-6). Pls Click Website Link as below: cas 15826-37-6 suppliers
Prev:Synthesis of isotactic polystyrene in hydrocarbons by initiation with t-BuLi in the presence of sodium dodecylbenzenesulfonate
Next:Full length articleCharacterization of impurities in Sodium cromoglycate (cas 15826-37-6) drug substance and eye drops using LC-ESI-ion trap MS and LC-ESI-QTOF MS) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Determination of Sodium cromoglycate (cas 15826-37-6) in human plasma by liquid chromatography–mass spectrometry in the turbo ion spray mode09/30/2019
- Effects of nebulized Sodium cromoglycate (cas 15826-37-6) on adult patients with severe refractory asthma09/29/2019
- Short communicationDevelopment and validation of an ion-pair liquid chromatographic method for the quantitation of Sodium cromoglycate (cas 15826-37-6) in urine following inhalation09/28/2019
- Equilibrium and kinetic aspects of Sodium cromoglycate (cas 15826-37-6) adsorption on chitosan: Mass uptake and surface charging considerations10/01/2019
- The mast cell stabilizer Sodium cromoglycate (cas 15826-37-6) reduces histamine release and status epilepticus-induced neuronal damage in the rat hippocampus09/27/2019
- Preliminary reportNasal Sodium cromoglycate (cas 15826-37-6) (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: A preliminary study09/26/2019
- Full length articleCharacterization of impurities in Sodium cromoglycate (cas 15826-37-6) drug substance and eye drops using LC-ESI-ion trap MS and LC-ESI-QTOF MS09/25/2019
-
Health and Chemical more >
-
Related Products
- Sodium 2,4-dimethylbenzenesulfonate
- SODIUM γ-FLUORO-β-HYDROXYBUTYRATE
- Sodium ((3-methoxy-1-methyl-3-oxo-1-propenyl)amino)phenylacetate
- Sodium (+)-10-camphorsulfonate
- Sodium (2-carbamoylphenoxy)acetate
- Sodium (2-methyl-4-chlorophenoxy)acetate
- Sodium (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate pentahydrate
- Sodium (C10-16)alkylbenzenesulfonate
- Sodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-
- Sodium (S)-lactate